Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dutasteride reduces DHT more effectively than finasteride, but finasteride is more commonly used and approved for hair loss. Users have mixed opinions on dutasteride's effectiveness, with some experiencing better results and others facing side effects or no improvement.

Minoxidil is on sale at Costco, but it poses a significant risk to pets, especially cats. Users discuss the pros and cons of foam versus liquid minoxidil, with some preferring liquid for better results despite its greasiness and dandruff issues.

If treatments like finasteride, minoxidil, PRP, microneedling, and exosomes fail, opinions differ on using a hair system or shaving. Some choose shaving for simplicity, while others consider hair systems despite maintenance concerns.

A 20-year-old is dealing with hair loss, using finasteride and oral minoxidil, and considering dutasteride. Others suggest treatments like dutasteride, hair transplants, therapy, and lifestyle changes to boost confidence and mental health.

A person started using finasteride, minoxidil, and dermarolling to regrow hair at the temples and is asking if it's possible. Some users report temple regrowth is possible with these treatments, while others find it challenging, and advise consistency and patience with treatment.

The conversation is about the double standard in the hair loss community regarding shedding when using different treatments. The conclusion is that shedding is considered normal when starting finasteride or minoxidil, but not when starting dutasteride, despite the fact that dutasteride is more effective at reducing DHT.

Creatine might increase DHT levels, potentially affecting hair loss, but its impact is debated. Some users experience hair shedding with creatine despite using finasteride, while others notice no change.

The efficacy of taking 1mg finasteride three times a week instead of daily for hair loss, with some users arguing that it is just as effective because finasteride has a long half-life in the scalp tissue and lower doses have been shown to be effective. Other users suggest experimenting with various treatments such as minoxidil and finasteride to achieve best results.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

Taking potassium chloride and magnesium stopped minoxidil-induced palpitations. The user is considering continuing minoxidil with these supplements.

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The conversation discusses reliable brands for RU58841, with recommendations for RUdirect and Receptorchem. Users also mention Anageninc as a known option for RU58841 in Europe and the UK.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.